Kenvue (NYSE:KVUE) Cut to Hold at Wall Street Zen

Wall Street Zen cut shares of Kenvue (NYSE:KVUE) from a buy rating to a hold rating in a research report released on Saturday morning.

Several other analysts also recently commented on the stock. Barclays raised their price objective on shares of Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 21st. Citigroup dropped their target price on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 15th. UBS Group increased their target price on shares of Kenvue from $18.00 to $20.00 and gave the stock a “neutral” rating in a research note on Thursday, July 16th. Zacks Research cut shares of Kenvue from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Finally, Weiss Ratings upgraded shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 15th. Three analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the company. According to data from MarketBeat.com, Kenvue currently has an average rating of “Hold” and a consensus price target of $19.36.

Kenvue Stock Down 1.2%

Shares of NYSE:KVUE opened at $19.00 on Friday. Kenvue has a 1 year low of $14.02 and a 1 year high of $21.95. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.01 and a quick ratio of 0.71. The business’s 50-day moving average is $18.80 and its 200-day moving average is $18.10. The company has a market capitalization of $36.49 billion, a price-to-earnings ratio of 21.84, a P/E/G ratio of 1.47 and a beta of 0.47.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, August 6th. The company reported $0.31 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.01). The business had revenue of $3.96 billion for the quarter, compared to analyst estimates of $3.97 billion. Kenvue had a return on equity of 21.22% and a net margin of 10.76%.The company’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same period in the prior year, the business earned $0.29 EPS. Equities research analysts predict that Kenvue will post 1.15 earnings per share for the current year.

Kenvue Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, August 26th. Investors of record on Wednesday, August 12th will be given a $0.21 dividend. This represents a $0.84 annualized dividend and a yield of 4.4%. The ex-dividend date of this dividend is Wednesday, August 12th. This is a positive change from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s payout ratio is 95.40%.

Hedge Funds Weigh In On Kenvue

Several large investors have recently bought and sold shares of the stock. Johnson Financial Group Inc. bought a new position in Kenvue during the second quarter valued at about $26,000. CoreCap Advisors LLC increased its holdings in Kenvue by 64.9% during the second quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock worth $29,000 after buying an additional 591 shares during the last quarter. Elyxium Wealth LLC bought a new stake in Kenvue in the fourth quarter worth about $26,000. Physician Wealth Advisors Inc. raised its position in Kenvue by 67.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after acquiring an additional 618 shares during the period. Finally, MV Capital Management Inc. purchased a new position in Kenvue in the fourth quarter valued at about $28,000. 97.64% of the stock is currently owned by institutional investors.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.